Gan & Lee Pharmaceuticals Achieves Significant Progress in Its Dual Pipeline for Metabolic Diseases -- Weekly Insulin Ludefen (GZR4) Meets Primary Endpoint in Phase III Clinical Trial in China; Bofanglutide Meets Primary Endpoints in Phase III Weight Loss Study in China and Phase II Study in the U.S.

Verified signal

Gan & Lee Pharmaceuticals.: 1 verified canonical event across 1 event type, supported by 1 independent source domain.

Why it matters

Verified with 1 independent source domain, 6 evidence object(s), 3 grounded fact(s), and confidence 0.80.

Confidence 0.80 · 1 independent source domain(s)

Evidence graph